| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037004 An aglycosylated antibody having a binding affinity for the CD3 antigen complex; antiinflammatory, antiarthritic agents |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050036991 For preventing and/or treating transplant/xenotransplant rejection; interleukin-1B converting enzyme inhibitors |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036949 A pharmaceutical dispenser; a liquid formulation comprising nitric oxide; respiratory system diseases; atomizing |
| 02/17/2005 | CA2844154A1 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | CA2807534A1 Methods of producing influenza vaccine compositions |
| 02/17/2005 | CA2678736A1 Novel multifunctional il-2 - il-18 fusion proteins |
| 02/17/2005 | CA2544240A1 Cpg-packaged liposomes |
| 02/17/2005 | CA2535125A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534496A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | CA2534471A1 Method and apparatus for producing ultrafine drug particles |
| 02/17/2005 | CA2533990A1 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 02/17/2005 | CA2533540A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 02/17/2005 | CA2533182A1 Dry syrup containing loratadine |
| 02/17/2005 | CA2531032A1 Programmed immune responses using a vaccination node |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506404A2 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506225A2 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus |
| 02/16/2005 | EP1506224A1 Polypeptide antigen inducing hiv neutralizing antibodies |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506198A1 5-ethylimidarotriazones |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506186A1 Substituted heterocyclic compounds and methods of use |
| 02/16/2005 | EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/16/2005 | EP1506040A2 Selective inos inhibitors for the treatment of respiratory diseases and conditions |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506010A2 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505982A1 Trimegestone and estrogens for treating post menopausal disorders |
| 02/16/2005 | EP1505979A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505963A1 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1505942A2 Pathogen vaccines and methods for using the same |
| 02/16/2005 | EP1425258A4 Hydroxyeicosenoic acid analogs |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 02/16/2005 | EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 02/16/2005 | EP1037906B1 Cyclopeptide derivatives with integrin inhibitor properties |
| 02/16/2005 | EP0957926B1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582288A Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 |
| 02/16/2005 | CN1582287A Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors |
| 02/16/2005 | CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| 02/16/2005 | CN1582276A Phenylalanine enamide derivatives |
| 02/16/2005 | CN1582269A Hydroxyeicosenoic acid analogs |
| 02/16/2005 | CN1582178A Hematopoietic stem cell gene therapy |
| 02/16/2005 | CN1582163A Method of administering a thymosin alpha 1 peptide |
| 02/16/2005 | CN1582162A Thymosin alpha 1 peptide/polymer conjugates |
| 02/16/2005 | CN1582161A Pharmatceutical Formualtion comprising cyclosporin and use thereof |
| 02/16/2005 | CN1582158A Novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases |
| 02/16/2005 | CN1582147A Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 02/16/2005 | CN1580068A Method for preparing injection ribonucleic acid of human placenta |
| 02/16/2005 | CN1580064A Tangeritin extracting technique |
| 02/16/2005 | CN1579537A Thymic peptide infusion and preparation process |
| 02/16/2005 | CN1579532A Method for extracting medicinal component of Yongchongcao |
| 02/16/2005 | CN1579491A Medicine for preventing allergy of dental natural characteristic |
| 02/16/2005 | CN1579387A Extraction of protopine from plant, and its manufacture of medicinal preparation and use |
| 02/16/2005 | CN1189557C Detecting and trapping receptor 3 monoclonal antibody, hybrid tumor for producing said antibody and its use |
| 02/16/2005 | CN1189467C Pharmaceutically active sulfonamide derivatives |
| 02/16/2005 | CN1189465C Vitamin D3 analogs with bis C-20 side chains |
| 02/16/2005 | CN1189216C Pharmaceutical compositions containing plasma protein |
| 02/16/2005 | CN1189215C Composition and formulation for solubilizing multiple compounds and preparation method thereof |
| 02/16/2005 | CN1189214C Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 02/16/2005 | CN1189213C Tolerance to xenograft |
| 02/16/2005 | CN1189207C Chinese medicainal composition for improving human immunity and its preparation method |
| 02/16/2005 | CN1189166C FC receptor modulators and uses thereof |
| 02/15/2005 | US6855806 Comprises secreted polypeptide for diagnosis and treatment of tumors, nervous system, reproductive and muscular disorder |
| 02/15/2005 | US6855736 Molecular target of neurotoxicity |
| 02/15/2005 | US6855719 Nitrogen compounds such as 2-(3-Chloroanilino)-4-(2-methyl-imidazo(1,2a)pyrid-3-yl)pyrimidine, used as cyclin dependent kinase inhibitors or as anticarcinogenic agents |
| 02/15/2005 | US6855713 Benzimidazole derivatives, a process for their manufacture and use as a medicine |
| 02/15/2005 | US6855712 Combination of benzoquinazoline antifolates and protecting agents |
| 02/15/2005 | US6855706 Phenylalanine derivatives |
| 02/15/2005 | US6855532 Gene therapy; drug screening |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855512 Phenylacetic or heteroarylacetic acid derivatives; retinoid like activity |
| 02/15/2005 | US6855492 Entrained antigen; oil in water emulsion; vaccine |
| 02/15/2005 | US6855350 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 02/15/2005 | US6855310 Aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of acetaminophen, orphenadrine or tramadol. |
| 02/15/2005 | US6854468 Treatment of subnormal bone mineral density |
| 02/15/2005 | CA2323720C New substances derived from aza-indolic polycyclics, processes for preparing them and pharmaceutical compounds containing them |
| 02/10/2005 | WO2005012543A2 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 02/10/2005 | WO2005012528A1 A method of preparing epitopes chimeric gene vaccine |
| 02/10/2005 | WO2005012294A1 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| 02/10/2005 | WO2005012268A1 Sulfonamide derivative having isoxazole ring |
| 02/10/2005 | WO2005012256A1 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 02/10/2005 | WO2005011813A2 Treatment of ocular disease |
| 02/10/2005 | WO2005011732A2 Rabbit bacterium and uses thereof |
| 02/10/2005 | WO2005011730A1 Microsome vaccine |